Ribometrix
- Company typePrivate
- Founded2016
- HeadquartersGreenville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Ribometrix firmographics
Firmographics- Name
- Ribometrix
- Legal name
- Ribometrix Inc.
- Website
- https://ribometrix.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Ribometrix industry classification
Industry- Product category
- Preclinical RNA-Targeting Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)
Keywords
Where Ribometrix is headquartered
LocationHeadquarters
- HQ city
- Greenville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ribometrix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Strategic Partnership Payments: Ribometrix generates revenue through strategic partnerships with pharmaceutical companies. These arrangements include upfront payments, research funding, milestone payments tied to development and regulatory achievements, and tiered royalties on net sales of any resulting products. The Vertex collaboration provides approximately $20 million upfront plus potential $700M+ in milestones and royalties. The Genentech collaboration provides $25 million upfront with potential milestones exceeding $1 billion.
- Internal Pipeline Development: The company is advancing wholly-owned programs including eIF4E and c-MYC targeting cancer indications. These programs aim to develop novel therapeutics that would be commercialized either independently or through future partnership arrangements upon achievement of clinical milestones.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Ribometrix product offering
Product offeringCore offering
Ribometrix is a preclinical platform therapeutics company that discovers and develops small molecule drugs which directly target cellular RNAs to modulate the production of disease-causing proteins. The company applies its proprietary 3D RNA structural analysis platform (SHAPE-MaP, RING-MaP) to identify druggable RNA structural hotspots and to discover small molecules that bind and selectively modulate these targets. Internal pipeline programs focus on oncology targets eIF4E and c-MYC, while external programs are advanced through strategic partnerships with major pharmaceutical companies.
Product overview
Ribometrix is a preclinical biotechnology company with a best-in-class platform for discovering and developing small molecule therapeutics that selectively bind and modulate cellular mRNAs to correct disease-causing protein expression. The company's core platform combines three main capabilities: (1) Rational Target Prioritization (RTP) for identifying druggable RNA structures, (2) RNA Modulation Through Binding Alone for discovering functional RNA binders, and (3) BOLSTR™ technology for engineering RNA-degrading functions into silent binders. The proprietary platform is applied across internal pipeline programs including the eIF4E inhibitor program (lead program RBX-6610) targeting multiple cancer indications, and the c-MYC mRNA-targeting program. Strategic collaborations with Genentech and Vertex leverage the discovery platform for additional therapeutic programs.
Differentiator
Problem solved
Functional benefit
Products and services
- RBX-6610 eIF4E Inhibitor Lead small molecule inhibitor of eukaryotic translation initiation factor 4E (eIF4E) being developed for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC), designed to re-sensitize tumors resistant to KRAS inhibitors when used in combination therapy. RBX-6610 has demonstrated anti-proliferative effects and synergistic apoptotic induction when combined with KRAS inhibitors in KRASG12C mutant NSCLC xenograft models.
- eIF4E Inhibitor Program Internal program developing small molecule inhibitors targeting the eukaryotic translation initiation factor 4E (eIF4E) RNA-binding protein for cancer treatment, with applications across melanoma, breast cancer, NSCLC, and colorectal cancer. IND filing planned for first half of 2025 with non-GLP toxicology studies completed and IND-enabling studies underway.
- c-MYC mRNA-Targeting Program Program developing small molecules that directly bind oncogenic c-MYC mRNA to reduce c-MYC protein expression, addressing a historically undruggable cancer target dysregulated in more than 70% of cancers through RNA targeting. Demonstrates direct binding of small molecules to c-MYC RNA and reduction of associated protein levels.
Quantifiable outcome
- RBX-6610 monotherapy caused 75% vs 71% TGI in treatment-naïve and resistant KRASG12C NSCLC xenograft models respectively
- +2 more outcomes
Companies that use Ribometrix
Customer profileSegments2 records
Ideal customer profiles1 record
Ribometrix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Ribometrix partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Genentech (Roche Group)flagshipExclusive worldwide license and collaboration agreement to discover, develop and commercialize small molecule drug candidates against several RNA targets. Ribometrix receives $25 million upfront payment and is eligible for potential milestone payments exceeding $1 billion, plus tiered royalties on future global net sales. Genentech is responsible for development and commercialization following discovery and preclinical development phases.
- Vertex PharmaceuticalscoreStrategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. Partnership combines Ribometrix's discovery platform with Vertex's scientific, clinical and regulatory capabilities for up to three therapeutic programs. Ribometrix receives $20 million upfront (including equity investment) with potential for more than $700 million in milestone payments and tiered royalties. Vertex has option to take exclusive global license for each program.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Ribometrix competitors and assessment
Company assessmentEmerging players
- Eloxx Pharmaceuticals: Develops small molecule read-through agents that target ribosome-RNA interactions for rare diseases. Adjacent to Ribometrix's RNA-targeting approach, demonstrating both the opportunity and challenges of small molecule RNA-targeting therapeutics.
- HiberCell: Focused on RNA biology and adaptive stress response in cancer. Comparable in leveraging RNA biology for oncology drug discovery, though with a distinct biological angle (stress response pathways) rather than direct RNA structural targeting.
- MiRagen Therapeutics (now Viridian Therapeutics): RNA-based therapeutics company where Ribometrix's new CEO William Marshall previously served as President and CEO. Comparable in RNA therapeutics modality focus and leadership lineage, providing a benchmark for development trajectories in RNA drug discovery.
Direct peers
- Accent Therapeutics: Develops small molecule therapeutics targeting RNA-modifying proteins for cancer. Comparable to Ribometrix in preclinical-to-clinical-stage RNA-targeted oncology pipeline and partnership-driven model (Lexicon partnership).
- Arrakis Therapeutics: Direct competitor developing small molecule drugs that bind RNA structures, with a focus on previously undruggable targets. Closely comparable to Ribometrix in modality (RNA-targeting small molecules), platform approach, and therapeutic focus on oncology and other diseases.
- Skyhawk Therapeutics: Develops small molecules that target RNA splicing for neurological diseases and oncology. Directly comparable to Ribometrix in RNA-targeting small molecule modality and partnership-driven business model, with multiple major pharma collaborations.
- Expansion Therapeutics: Pursues small molecule therapeutics targeting RNA-repeat expansion disorders. Comparable in small molecule RNA-targeting approach and preclinical stage, though focused on neurological repeat expansion diseases rather than oncology.
- Remix Therapeutics: Uses REM-seq platform to identify small molecules that modulate RNA processing. Closely comparable to Ribometrix's approach of using RNA biology to discover small molecule therapeutics, with overlapping oncology focus and similar partnership-driven strategy.
- Twentyeight-Seven Therapeutics: Targets RNA-modifying proteins (particularly METTL3) with small molecules for cancer. Comparable in combining RNA biology insights with small molecule drug discovery, with a focus on oncology similar to Ribometrix's eIF4E and c-MYC programs.
- Storm Therapeutics: Pioneer in RNA epitranscriptomics with small molecule inhibitors targeting RNA-modifying enzymes. Comparable in RNA-focused small molecule discovery for oncology, though with a distinct mechanistic angle (epitranscriptomics rather than direct RNA binding).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Ribometrix social profiles
Digital presenceRibometrix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ribometrix leadership team
Management profileNumber of profiles
Profiles13 records
Ribometrix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ribometrix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ribometrix
What does Ribometrix do?
Ribometrix is a preclinical platform therapeutics company that discovers and develops small molecule drugs which directly target cellular RNAs to modulate the production of disease-causing proteins. The company applies its proprietary 3D RNA structural analysis platform (SHAPE-MaP, RING-MaP) to identify druggable RNA structural hotspots and to discover small molecules that bind and selectively modulate these targets. Internal pipeline programs focus on oncology targets eIF4E and c-MYC, while external programs are advanced through strategic partnerships with major pharmaceutical companies.
Is Ribometrix a public or private company?
Ribometrix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ribometrix founded?
Ribometrix was founded in 2016. It employs 11 to 50 people.
Where is Ribometrix based?
Ribometrix is headquartered in Greenville, United States, in the North America region.
How does Ribometrix make money?
Two revenue lines are on record. Strategic Partnership Payments are the primary driver. The others are internal Pipeline Development.
Who are Ribometrix's main competitors?
Emerging players on record are Eloxx Pharmaceuticals, HiberCell and MiRagen Therapeutics (now Viridian Therapeutics). Direct peers are Accent Therapeutics, Arrakis Therapeutics, Skyhawk Therapeutics, Expansion Therapeutics, Remix Therapeutics, Twentyeight-Seven Therapeutics and Storm Therapeutics.
Does Ribometrix have an API?
No public API is recorded for Ribometrix.
What industry is Ribometrix in?
Ribometrix's product category is Preclinical RNA-Targeting Drug Discovery. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714 and its SIC code is 8731.